Apellis Pharmaceuticals, Inc.NASDAQ: APLS

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)

· Issued by Apellis Pharmaceuticals, Inc.
Watch Apellis Pharmaceuticals explain itApellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24
  • Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal)
    • DERBY: 36% monthly, p